Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
J Allergy Clin Immunol ; 153(1): 330-334, 2024 01.
Article in English | MEDLINE | ID: mdl-37678573

ABSTRACT

BACKGROUND: Newborn screening (NBS) programs for severe combined immunodeficiency facilitate early diagnosis of severe combined immunodeficiency and promote early treatment with hematopoietic stem cell transplantation, resulting in improved clinical outcomes. Infants with congenital athymia are also identified through NBS because of severe T-cell lymphopenia. With the expanding introduction of NBS programs, referrals of athymic patients for treatment with thymus transplantation have recently increased at Great Ormond Street Hospital (GOSH) (London, United Kingdom). OBJECTIVE: We studied the impact of NBS on timely diagnosis and treatment of athymic infants with thymus transplantation at GOSH. METHODS: We compared age at referral and complications between athymic infants diagnosed after clinical presentation (n = 25) and infants identified through NBS (n = 19) who were referred for thymus transplantation at GOSH between October 2019 and February 2023. We assessed whether age at time of treatment influences thymic output at 6 and 12 months after transplantation. RESULTS: The infants referred after identification through NBS were significantly younger and had fewer complications, in particular fewer infections. All deaths occurred in the group of those who did not undergo NBS, including 6 patients before and 2 after thymus transplantation because of preexisting infections. In the absence of significant comorbidities or diagnostic uncertainties, timely treatment was achieved more frequently after NBS. Treatment when younger than age 4 months was associated with higher thymic output at 6 and 12 months after transplantation. CONCLUSION: NBS contributes to earlier recognition of congenital athymia, promoting referral of athymic patients for thymus transplantation before they acquire infections or other complications and facilitating treatment at a younger age, thus playing an important role in improving their outcomes.


Subject(s)
Immunologic Deficiency Syndromes , Severe Combined Immunodeficiency , Infant , Infant, Newborn , Humans , Severe Combined Immunodeficiency/diagnosis , Severe Combined Immunodeficiency/therapy , Neonatal Screening , Thymus Gland
2.
J Allergy Clin Immunol Pract ; 11(8): 2476-2483, 2023 08.
Article in English | MEDLINE | ID: mdl-37146882

ABSTRACT

BACKGROUND: Detailed demographic data on people with hereditary angioedema (HAE) and acquired C1 inhibitor deficiency in the United Kingdom are relatively limited. Better demographic data would be beneficial in planning service provision, identifying areas of improvement, and improving care. OBJECTIVE: To obtain more accurate data on the demographics of HAE and acquired C1 inhibitor deficiency in the United Kingdom, including treatment modalities and services available to patients. METHODS: A survey was distributed to all centers in the United Kingdom that look after patients with HAE and acquired C1 inhibitor deficiency to collect these data. RESULTS: The survey identified 1152 patients with HAE-1/2 (58% female and 92% type 1), 22 patients with HAE with normal C1 inhibitor, and 91 patients with acquired C1 inhibitor deficiency. Data were provided by 37 centers across the United Kingdom. This gives a minimum prevalence of 1:59,000 for HAE-1/2 and 1:734,000 for acquired C1 inhibitor deficiency in the United Kingdom. A total of 45% of patients with HAE were on long-term prophylaxis (LTP) with the most used medication being danazol (55% of all patients on LTP). Eighty-two percent of patients with HAE had a home supply of acute treatment with C1 inhibitor or icatibant. A total of 45% of patients had a supply of icatibant and 56% had a supply of C1 inhibitor at home. CONCLUSIONS: Data obtained from the survey provide useful information about the demographics and treatment modalities used in HAE and acquired C1 inhibitor deficiency in the United Kingdom. These data are useful for planning service provision and improving services for these patients.


Subject(s)
Angioedemas, Hereditary , Humans , Female , Male , Angioedemas, Hereditary/epidemiology , Angioedemas, Hereditary/drug therapy , Complement C1 Inhibitor Protein/therapeutic use , Danazol/therapeutic use , United Kingdom/epidemiology , Surveys and Questionnaires
3.
J Allergy Clin Immunol ; 151(4): 1081-1095, 2023 04.
Article in English | MEDLINE | ID: mdl-36228738

ABSTRACT

BACKGROUND: In 2014, germline signal transducer and activator of transcription (STAT) 3 gain-of-function (GOF) mutations were first described to cause a novel multisystem disease of early-onset lymphoproliferation and autoimmunity. OBJECTIVE: This pivotal cohort study defines the scope, natural history, treatment, and overall survival of a large global cohort of patients with pathogenic STAT3 GOF variants. METHODS: We identified 191 patients from 33 countries with 72 unique mutations. Inclusion criteria included symptoms of immune dysregulation and a biochemically confirmed germline heterozygous GOF variant in STAT3. RESULTS: Overall survival was 88%, median age at onset of symptoms was 2.3 years, and median age at diagnosis was 12 years. Immune dysregulatory features were present in all patients: lymphoproliferation was the most common manifestation (73%); increased frequencies of double-negative (CD4-CD8-) T cells were found in 83% of patients tested. Autoimmune cytopenias were the second most common clinical manifestation (67%), followed by growth delay, enteropathy, skin disease, pulmonary disease, endocrinopathy, arthritis, autoimmune hepatitis, neurologic disease, vasculopathy, renal disease, and malignancy. Infections were reported in 72% of the cohort. A cellular and humoral immunodeficiency was observed in 37% and 51% of patients, respectively. Clinical symptoms dramatically improved in patients treated with JAK inhibitors, while a variety of other immunomodulatory treatment modalities were less efficacious. Thus far, 23 patients have undergone bone marrow transplantation, with a 62% survival rate. CONCLUSION: STAT3 GOF patients present with a wide array of immune-mediated disease including lymphoproliferation, autoimmune cytopenias, and multisystem autoimmunity. Patient care tends to be siloed, without a clear treatment strategy. Thus, early identification and prompt treatment implementation are lifesaving for STAT3 GOF syndrome.


Subject(s)
Immune System Diseases , Immunologic Deficiency Syndromes , Child , Humans , Autoimmunity/genetics , Cohort Studies , Gain of Function Mutation , Immunologic Deficiency Syndromes/genetics , Mutation , STAT3 Transcription Factor/genetics , Cell Proliferation , Lymphocytes
4.
J Clin Immunol ; 42(3): 665-671, 2022 04.
Article in English | MEDLINE | ID: mdl-35084692

ABSTRACT

BACKGROUND: Terminal complement pathway deficiencies often present with severe and recurrent infections. There is a lack of good-quality data on these rare conditions. This study investigated the clinical outcome and genetic variation in a large UK multi-center cohort with primary and secondary terminal complement deficiencies. METHODS: Clinicians from seven UK centers provided anonymised demographic, clinical, and laboratory data on patients with terminal complement deficiencies, which were collated and analysed. RESULTS: Forty patients, median age 19 (range 3-62) years, were identified with terminal complement deficiencies. Ten (62%) of 16 patients with low serum C5 concentrations had underlying pathogenic CFH or CFI gene variants. Two-thirds were from consanguineous Asian families, and 80% had an affected family member. The median age of the first infection was 9 years. Forty-three percent suffered meningococcal serotype B and 43% serotype Y infections. Nine (22%) were treated in intensive care for meningococcal septicaemia. Two patients had died, one from intercurrent COVID-19. Twenty-one (52%) were asymptomatic and diagnosed based on family history. All but one patient had received booster meningococcal vaccines and 70% were taking prophylactic antibiotics. DISCUSSION: The genetic etiology and clinical course of patients with primary and secondary terminal complement deficiency are variable. Patients with low antigenic C5 concentrations require genetic testing, as the low level may reflect consumption secondary to regulatory defects in the pathway. Screening of siblings is important. Only half of the patients develop septicaemia, but all should have a clear management plan.


Subject(s)
COVID-19 , Meningococcal Infections , Sepsis , Adolescent , Adult , Child , Child, Preschool , Cohort Studies , Complement System Proteins/genetics , Hereditary Complement Deficiency Diseases , Humans , Meningococcal Infections/genetics , Middle Aged , United Kingdom/epidemiology , Young Adult
5.
Immunity ; 53(2): 353-370.e8, 2020 08 18.
Article in English | MEDLINE | ID: mdl-32735845

ABSTRACT

The formation of mammalian dendritic cells (DCs) is controlled by multiple hematopoietic transcription factors, including IRF8. Loss of IRF8 exerts a differential effect on DC subsets, including plasmacytoid DCs (pDCs) and the classical DC lineages cDC1 and cDC2. In humans, cDC2-related subsets have been described including AXL+SIGLEC6+ pre-DC, DC2 and DC3. The origin of this heterogeneity is unknown. Using high-dimensional analysis, in vitro differentiation, and an allelic series of human IRF8 deficiency, we demonstrated that cDC2 (CD1c+DC) heterogeneity originates from two distinct pathways of development. The lymphoid-primed IRF8hi pathway, marked by CD123 and BTLA, carried pDC, cDC1, and DC2 trajectories, while the common myeloid IRF8lo pathway, expressing SIRPA, formed DC3s and monocytes. We traced distinct trajectories through the granulocyte-macrophage progenitor (GMP) compartment showing that AXL+SIGLEC6+ pre-DCs mapped exclusively to the DC2 pathway. In keeping with their lower requirement for IRF8, DC3s expand to replace DC2s in human partial IRF8 deficiency.


Subject(s)
Antigens, CD34/metabolism , Dendritic Cells/cytology , Hematopoiesis/physiology , Interferon Regulatory Factors/metabolism , Animals , Antigens, CD1/metabolism , Cell Line , Cell Lineage/immunology , Dendritic Cells/immunology , Glycoproteins/metabolism , Hematopoietic Stem Cells/cytology , Humans , Interleukin-3 Receptor alpha Subunit/metabolism , Lipopolysaccharide Receptors/metabolism , Mice , Receptors, Immunologic/metabolism
6.
Hepatology ; 71(2): 422-430, 2020 02.
Article in English | MEDLINE | ID: mdl-31220349

ABSTRACT

For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct-acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir-sofosbuvir in HCV-infected children aged 3 to <6 years. In an open-label study, patients 3 to <6 years old chronically infected with HCV genotype 1 (n = 33) or 4 (n = 1) received weight-based doses of combined ledipasvir-sofosbuvir as granules (33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12). For the first 14 patients, intensive pharmacokinetic sampling was done on day 10 of treatment. All patients had been infected through perinatal transmission and were treatment naïve. No patients had known cirrhosis. Ten patients (29%) weighed <17 kg. SVR12 was achieved in 97% of patients (33 of 34); the patient who did not achieve SVR12 was 3 years old and discontinued treatment after 5 days because of an adverse event "abnormal drug taste." The most common adverse events were vomiting (24% of patients), cough (21%), and pyrexia (21%). No patients experienced a serious adverse event. Intensive pharmacokinetic analysis of 13 patients for whom data were evaluable confirmed that the doses selected were appropriate. Conclusion: Ledipasvir-sofosbuvir was well tolerated and highly effective in children 3 to <6 years old with chronic HCV infection.


Subject(s)
Antiviral Agents/administration & dosage , Benzimidazoles/administration & dosage , Fluorenes/administration & dosage , Hepatitis C, Chronic/drug therapy , Uridine Monophosphate/analogs & derivatives , Antiviral Agents/adverse effects , Benzimidazoles/adverse effects , Child , Child, Preschool , Female , Fluorenes/adverse effects , Humans , Male , Sofosbuvir , Sustained Virologic Response , Time Factors , Treatment Outcome , Uridine Monophosphate/administration & dosage , Uridine Monophosphate/adverse effects
7.
Clin Immunol ; 210: 108316, 2020 01.
Article in English | MEDLINE | ID: mdl-31770611

ABSTRACT

Germline STAT3 gain-of-function (GOF) mutations have been linked to poly-autoimmunity and lymphoproliferation with variable expressivity and incomplete penetrance. Here we studied the impact of 17 different STAT3 GOF mutations on the canonical STAT3 signaling pathway and correlated the molecular results with clinical manifestations. The mutations clustered in three groups. Group 1 mutants showed altered STAT3 phosphorylation kinetics and strong basal transcriptional activity. They were associated with the highest penetrance of lymphoproliferation and autoimmunity. Group 2 mutants showed a strongly inducible transcriptional reporter activity and were clinically less penetrant. Group 3 mutants were mostly located in the DNA binding domain and showed the strongest DNA binding affinity despite a poor transcriptional reporter response. Thus, the GOF effect of STAT3 mutations is determined by a heterogeneous response pattern at the molecular level. The correlation of response pattern and clinical penetrance indicates a significant contribution of mutation-determined effects on disease manifestations.


Subject(s)
Gain of Function Mutation/genetics , Lymphocytes/immunology , STAT3 Transcription Factor/genetics , Autoimmunity/genetics , Cell Proliferation , Female , Humans , Male , Multigene Family , Penetrance , Phosphorylation , STAT3 Transcription Factor/metabolism , Signal Transduction/genetics
9.
Front Immunol ; 10: 568, 2019.
Article in English | MEDLINE | ID: mdl-31057532

ABSTRACT

Common variable immunodeficiency (CVID) is the most frequent symptomatic primary immunodeficiency. Patients with CVID are prone to recurrent bacterial infection due to the failure of adequate immunoglobulin production. Monogenetic defects have been identified in ~25% of CVID patients. Recently, mutations in IKZF1, encoding the zinc-finger transcription factor IKAROS which is broadly expressed in hematopoietic cells, have been associated with a CVID-like phenotype. Herein we describe 11 patients with heterozygous IKZF1 variants from eight different families with autosomal dominant CVID and two siblings with an IKZF1 variant presenting with inflammatory bowel disease (IBD). This study shows that mutations affecting the DNA binding domain of IKAROS can impair the interaction with the target DNA sequence thereby preventing heterochromatin and pericentromeric localization (HC-PC) of the protein. Our results also indicate an impairment of pericentromeric localization of IKAROS by overexpression of a truncated variant, caused by an immature stop codon in IKZF1. We also describe an additional variant in TNFSF10, encoding Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL), additionally presented in individuals of Family A. Our results indicate that this variant may impair the TRAIL-induced apoptosis in target cell lines and prohibit the NFκB activation by TRAIL and may act as a modifier in Family A.


Subject(s)
Common Variable Immunodeficiency/genetics , Ikaros Transcription Factor/genetics , Mutation , Respiratory Tract Infections/genetics , Zinc Fingers , Adult , Animals , Antibodies/immunology , Binding Sites/genetics , Cell Nucleus/metabolism , Centromere/metabolism , Cohort Studies , Common Variable Immunodeficiency/immunology , DNA/metabolism , DNA Mutational Analysis , Female , HEK293 Cells , Heterozygote , Humans , Ikaros Transcription Factor/metabolism , Inflammatory Bowel Diseases/genetics , Male , Mice , Middle Aged , NIH 3T3 Cells , Pedigree , Phenotype , Respiratory Tract Infections/immunology
10.
Arch Dis Child Educ Pract Ed ; 103(5): 231-235, 2018 10.
Article in English | MEDLINE | ID: mdl-29475900

ABSTRACT

Low or absent immunoglobulin A (IgA) levels are frequently found in children in whom immunodeficiency is not suspected. IgA deficiency is the most common primary immunodeficiency disorder in the UK affecting approximately 1 in 600 people. Isolated IgA deficiency is often identified coincidentally when investigating a child for conditions such as coeliac disease. The aim of this article is to provide a structured approach to the history, investigation and management of an isolated IgA deficiency.


Subject(s)
IgA Deficiency/diagnosis , Incidental Findings , Asymptomatic Diseases , Child , Humans , IgA Deficiency/etiology , Transfusion Reaction
11.
J Infect Public Health ; 10(4): 470-478, 2017.
Article in English | MEDLINE | ID: mdl-27568000

ABSTRACT

This paper describes a voluntary anonymous survey to investigate the seroprevalence of Hepatitis C (HCV) in children in Glasgow, UK attending a Dental Hospital and the proportion of HCV positive mothers who have a child who is HCV seropositive. The study was undertaken among children and accompanying parents and household contacts attending a general anaesthetic assessment clinic at Glasgow Dental Hospital and School. Children were asked to provide an oral fluid specimen for HCV testing. Accompanying adults were asked to provide demographic data on the child and information on familial risk factors for HCV infection using a standardised questionnaire. Birth mothers were also asked to provide an oral fluid specimen. Specimens and questionnaires were linked by a unique anonymous study number. Between June 2009 and December 2011, samples were collected from 2141 children and 1698 mothers. None of the samples from the children were HCV seropositive but 16 (0.9%, 95% CI 0.6-1.5%) of the specimens from mothers were HCV antibody positive. In summary, the prevalence of HCV seropositivity in the birth mothers of the children was similar to that estimated in the general population served by the hospital and showed no evidence of mother-to-child transmission of HCV.


Subject(s)
Hepatitis C Antibodies/analysis , Hepatitis C/epidemiology , Saliva/chemistry , Adolescent , Adult , Child , Child, Preschool , Cohort Studies , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Scotland/epidemiology , Seroepidemiologic Studies , Surveys and Questionnaires
12.
J Allergy Clin Immunol ; 139(2): 597-606.e4, 2017 02.
Article in English | MEDLINE | ID: mdl-27555459

ABSTRACT

BACKGROUND: Activated phosphoinositide 3-kinase δ syndrome (APDS) is a recently described combined immunodeficiency resulting from gain-of-function mutations in PIK3CD, the gene encoding the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ). OBJECTIVE: We sought to review the clinical, immunologic, histopathologic, and radiologic features of APDS in a large genetically defined international cohort. METHODS: We applied a clinical questionnaire and performed review of medical notes, radiology, histopathology, and laboratory investigations of 53 patients with APDS. RESULTS: Recurrent sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were common, often from childhood. Other significant complications included herpesvirus infections (49%), autoinflammatory disease (34%), and lymphoma (13%). Unexpectedly, neurodevelopmental delay occurred in 19% of the cohort, suggesting a role for PI3Kδ in the central nervous system; consistent with this, PI3Kδ is broadly expressed in the developing murine central nervous system. Thoracic imaging revealed high rates of mosaic attenuation (90%) and bronchiectasis (60%). Increased IgM levels (78%), IgG deficiency (43%), and CD4 lymphopenia (84%) were significant immunologic features. No immunologic marker reliably predicted clinical severity, which ranged from asymptomatic to death in early childhood. The majority of patients received immunoglobulin replacement and antibiotic prophylaxis, and 5 patients underwent hematopoietic stem cell transplantation. Five patients died from complications of APDS. CONCLUSION: APDS is a combined immunodeficiency with multiple clinical manifestations, many with incomplete penetrance and others with variable expressivity. The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease. Clinical trials of selective PI3Kδ inhibitors offer new prospects for APDS treatment.


Subject(s)
Class I Phosphatidylinositol 3-Kinases/genetics , Immunologic Deficiency Syndromes/genetics , Lymphoproliferative Disorders/genetics , Mutation/genetics , Respiratory Tract Infections/genetics , Adolescent , Adult , Animals , Antibiotic Prophylaxis , Child , Child, Preschool , Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors , Cohort Studies , Enzyme Inhibitors/therapeutic use , Female , Hematopoietic Stem Cell Transplantation , Herpesviridae Infections/genetics , Herpesviridae Infections/mortality , Herpesviridae Infections/therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Deficiency Syndromes/mortality , Immunologic Deficiency Syndromes/therapy , Infant , International Cooperation , Lymphoproliferative Disorders/mortality , Lymphoproliferative Disorders/therapy , Male , Mice , Middle Aged , Recurrence , Respiratory Tract Infections/mortality , Respiratory Tract Infections/therapy , Surveys and Questionnaires , Survival Analysis , Young Adult
14.
Practitioner ; 259(1784): 17-21, 2-3, 2015.
Article in English | MEDLINE | ID: mdl-26514056

ABSTRACT

Most illnesses associated with fever are self-limiting and children recover with no specific treatment. However, fever can also be the presenting feature of serious illness, which may be life threatening if not diagnosed and treated appropriately. It is important to establish whether the temperature has been measured and, if so, how. The height of the temperature should be recorded, and always enquire what device has been used, as a reading from a forehead thermometer may not be accurate. While many families will use a thermometer the impression of the child being hot to touch without formal measurement should still be taken seriously. Check whether the child is still feeding or taking fluids adequately. Any child may be irritable when their temperature is high, but a constantly irritable or inconsolable child, or one who is extremely lethargic, drowsy or difficult to rouse is a cause for concern. Ask about any skin changes or rashes the parent may have noticed. Find out what measures the parent may already have taken to manage the fever, and in particular, whether, and at what time, antipyretics have been given. Enquire about contact with infectious illnesses, and foreign travel. Other vital signs, including heart rate, respiratory rate and capillary refill time should also be recorded. The child should be examined for focal signs indicating the site of infection, and hydration should be assessed. Posture, tone, fontanelle (if patent), presence of a rash, neck stiffness and level of consciousness should also be assessed. If the diagnosis is unclear, potentially serious, and specific treatment may be needed to prevent deterioration, the child should be referred.


Subject(s)
Fever , Child , Fever/diagnosis , Fever/etiology , Fever/therapy , Humans
15.
J Clin Immunol ; 35(4): 366-72, 2015 May.
Article in English | MEDLINE | ID: mdl-25875700

ABSTRACT

PURPOSE: Adenosine deaminase (ADA) deficiency is a systemic disorder of purine metabolism. Deficiency of the purine salvage enzyme ADA leads to the build-up of the toxic metabolites, deoxyadenosine triphosphate and deoxyadenosine. ADA is ubiquitously expressed in all tissues of the body but most profoundly affects lymphocyte development and function leading to severe combined immunodeficiency (SCID). Unlike most other forms of SCID, ADA deficiency also results in non-immunologic manifestations. Associations between ADA deficiency and sensorineural hearing loss, behavioural abnormalities, non-infectious pulmonary disease and skeletal dysplasia are all recognised, and affect the long term outcome for these patients. Identification of new non-immunological manifestations and clinical presentations of ADA deficiency is essential to allow early optimisation of supportive care. METHODS AND RESULTS: Here we report four patients with ADA deficiency whose presenting feature was haemolytic uremic syndrome (HUS). 3 of 4 patients were diagnosed with ADA deficiency only after developing HUS, and one diagnosis was made post mortem, after a sibling was diagnosed with SCID. Shiga-toxigenic organisms were not isolated from any of the patients. 2 patients made a good recovery from their HUS with supportive treatment and initiation of PEG-ADA. Both remain well on enzyme replacement with mild or no residual renal impairment. CONCLUSIONS: Clinicians should be aware of this previously unreported non-immunologic manifestation of ADA deficiency.


Subject(s)
Adenosine Deaminase/deficiency , Agammaglobulinemia/diagnosis , Atypical Hemolytic Uremic Syndrome/diagnosis , Severe Combined Immunodeficiency/diagnosis , Adenosine Deaminase/genetics , Agammaglobulinemia/drug therapy , Child , Diagnosis, Differential , Fatal Outcome , Female , Genotype , Humans , Infant , Male , Mutation , Severe Combined Immunodeficiency/drug therapy
16.
Practitioner ; 258(1772): 15-8, 2, 2014 Jun.
Article in English | MEDLINE | ID: mdl-25102572

ABSTRACT

Neisseria meningitidis is an encapsulated Gram-negative diplococcus which colonises the upper respiratory tract without causing symptoms in up to 25% of the population. At least 13 different serogroups cause invasive meningococcal disease (IND). In the UK serogroup B causes more than 80% of cases of invasive disease. More than 75% of cases occur in the under 5s, reflecting the lack of ability of the immature immune system to mount an effective response to the polysaccharide capsule of the organism. There is also a peak around adolescence. Meningococcal disease can present with features of septicaemia, fever, purpura, and rapidly progressive shock, or with meningitis which can occur without a rash. Many cases have a mixed picture. Young infants with meningitis may not display the classical signs, but appear unwell, lethargic and floppy Petechiae which start to spread, become purpuric, occur in association with signs of shock or meningitis, or in any child who appears ill should always be treated as IMD until proven otherwise. Any child with symptoms and signs suggestive of IMD and a non-blanching rash should be transferred to hospital as an emergency immediately. IM (or IV) benzylpenicillin (or ceftriaxone) should be given at the earliest opportunity, but treatment should not delay transfer. if the child does not have features suggestive of IMD at the time of initial assessment it is important to give parents advice regarding symptoms and signs which may suggest deterioration.


Subject(s)
Meningococcal Infections/diagnosis , Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Child , Humans , Meningococcal Infections/drug therapy , Meningococcal Infections/prevention & control , Meningococcal Vaccines/therapeutic use , Penicillin G/therapeutic use
17.
J Crohns Colitis ; 7(4): 314-7, 2013 May.
Article in English | MEDLINE | ID: mdl-22640698

ABSTRACT

We report a case of Epstein-Barr virus infection with the subsequent development of haemophagocytic lymphohistiocytosis in a teenage Crohn's disease patient treated with azathioprine. We found that the early introduction of the anti-B cell monoclonal antibody rituximab precipitated a rapid fall in circulating B-cells and EBV viral load, resulting in a prompt and sustained recovery from what is a potentially fatal complication of azathioprine therapy in Crohn's disease patients.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Azathioprine/adverse effects , Crohn Disease/drug therapy , Epstein-Barr Virus Infections/drug therapy , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Lymphohistiocytosis, Hemophagocytic/drug therapy , Adolescent , Azathioprine/therapeutic use , Crohn Disease/complications , Crohn Disease/immunology , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/immunology , Female , Humans , Immunologic Factors/therapeutic use , Immunosuppressive Agents/therapeutic use , Lymphohistiocytosis, Hemophagocytic/complications , Lymphohistiocytosis, Hemophagocytic/immunology , Lymphohistiocytosis, Hemophagocytic/virology , Rituximab
18.
J Infect Dis ; 207(4): 588-93, 2013 Feb 15.
Article in English | MEDLINE | ID: mdl-23087434

ABSTRACT

We investigated oral fluid (OF) as an alternative to sampling of rashes for varicella zoster virus (VZV) genotyping and further characterized VZV clade prevalence in the United Kingdom and Europe. VZV was detected in up to 91% of OF specimens. Paired OF and vesicle fluid samples contained identical VZV clades. While clades 1 and 3 were the most prevalent across the United Kingdom and Europe, in Western Europe, clade 5 viruses were circulating. Viruses from the same outbreak belonged to different clades, but no clade was associated with a severe-disease phenotype. OF is suitable and convenient for large-scale molecular epidemiological studies of VZV.


Subject(s)
Chickenpox/epidemiology , Herpes Zoster/epidemiology , Herpesvirus 3, Human/genetics , Molecular Epidemiology , Polymorphism, Single Nucleotide , Saliva/virology , Chickenpox/virology , Europe/epidemiology , Genotype , Herpes Zoster/virology , Herpesvirus 3, Human/isolation & purification , Humans , Mouth/virology , Prevalence , Sensitivity and Specificity , Skin/pathology , Skin/virology , United Kingdom/epidemiology
19.
Clin Chem ; 57(4): 593-602, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21273509

ABSTRACT

BACKGROUND: Determination of the genetic defect in patients with a congenital disorder of glycosylation (CDG) is challenging because of the wide clinical presentation, the large number of gene products involved, and the occurrence of secondary causes of underglycosylation. Transferrin isoelectric focusing has been the method of choice for CDG screening; however, improved methods are required for the molecular diagnosis of patients with CDG type II. METHODS: Plasma samples with a typical transferrin isofocusing profile were analyzed. N-glycans were released from these samples by PNGase F [peptide-N4-(acetyl-ß-glucosaminyl)-asparagine amidase] digestion, permethylated and purified, and measured on a MALDI linear ion trap mass spectrometer. A set of 38 glycans was used for quantitative comparison and to establish reference intervals for such glycan features as the number of antennae, the level of truncation, and fucosylation. Plasma N-glycans from control individuals, patients with known CDG type II defects, and patients with a secondary cause of underglycosylation were analyzed. RESULTS: CDGs due to mannosyl (α-1,6-)-glycoprotein ß-1,2-N-acetylglucosaminyltransferase (MGAT2), ß-1,4-galactosyltransferase 1 (B4GALT1), and SLC35C1 (a GDP-fucose transporter) defects could be diagnosed directly from the N-glycan profile. CDGs due to defects in proteins involved in Golgi trafficking, such as subunit 7 of the conserved oligomeric Golgi complex (COG7) and subunit V0 a2 of the lysosomal H(+)-transporting ATPase (ATP6V0A2) caused a loss of triantennary N-glycans and an increase of truncated structures. Secondary causes with liver involvement were characterized by increased fucosylation, whereas the presence of plasma sialidase produced isolated undersialylation. CONCLUSIONS: MALDI ion trap analysis of plasma N-glycans documents features that discriminate between primary and secondary causes of underglycosylation and should be applied as the first step in the diagnostic track of all patients with an unsolved CDG type II.


Subject(s)
Congenital Disorders of Glycosylation/diagnosis , Polysaccharides/blood , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Case-Control Studies , Congenital Disorders of Glycosylation/blood , Humans , Infant, Newborn , Neonatal Screening
SELECTION OF CITATIONS
SEARCH DETAIL
...